Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nav1.8 inhibitor (Grünenthal)
- Development stage
- Unknown
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nav1.8 inhibitor (Grünenthal) is an orally bioavailable small molecule designed to selectively inhibit the voltage-gated sodium channel 1.8 (Nav1.8), also known as SCN10A. Developed by Grünenthal and its US subsidiary Averitas Pharma, the compound is currently in clinical development for the treatment of chronic pain. Nav1.8 is a sodium channel subtype primarily expressed in peripheral nociceptive neurons of the dorsal root ganglia, where it plays a critical role in the transmission of pain signals. By selectively blocking this channel, the drug aims to reduce neuronal hyperexcitability and provide potent analgesia while avoiding the central nervous system and cardiovascular side effects typically associated with non-selective sodium channel blockers.
- Other names
- SCN10A inhibitorSCN-10A inhibitorSCN 10A inhibitorVoltage-gated sodium channel 1.8 inhibitor
02
Targets
SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on Nav1.8 inhibitor (Grünenthal).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nav1.8 inhibitor (Grünenthal).